This page shows the latest Nesina news and features for those working in and with pharma, biotech and healthcare.
Those concerns have caused warnings to be imposed on some rival drugs, namely AstraZeneca's Onglyza (saxagliptin) and Takeda's Nesina (alogliptin).
Earlier this year FDA advisers recommended two DPP-4 inhibitors, AstraZeneca's Onglyza (saxagliptin) and Takeda's Nesina (alogliptin), should have their labelling updated to indicate a link to heart failure.
Approximately 3 fully matching, plus 17 partially matching documents found.